ClinicalTrials.gg
Not yet recruitingNCT05904925Updated Jun 15, 2023

Pilates for the Prevention of Musculoskeletal Complaints During Pregnancy

An interventional study of Pilates exercises in Pregnancy, sponsored by Universidade Cidade de Sao Paulo. Not yet recruiting. Open to female participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-06-15.

Sponsored by Universidade Cidade de Sao Paulo · Not applicable, Interventional, and Other

From the registry’s dates

  • Primary completion was expected by Jun 2024, 2 years 4 months ago, but the record still lists the study as not yet recruiting.
Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
Female
01

Study summary

The goal of this pilot randomized controlled trial with economic evaluation is to evaluate the viability of Pilates in the prevention of musculoskeletal complaints, throughout the entire gestational period, in pregnant women. The main question it aims to answer is if it is feasible to perform exercises during the entire gestational period to prevent musculoskeletal disorders. Participants will be assessed primarily for acceptability, suitability, feasibility, and fidelity, and secondarily for the occurrence of musculoskeletal complaint and the number of days from randomization on which this musculoskeletal complaint occurred, type of delivery and costs. Then, participants will be randomized into two groups: the usual care group, which will receive an educational booklet with information about the usual care during pregnancy, and the Pilates group, which will receive the same educational booklet and will participate in a specific Pilates exercise program for the gestational period, twice a week, throughout the pregnancy.

02

Conditions studied

  • Pregnancy

Keywords

  • Pilates
  • Pregnancy
  • Randomized controlled trial
  • Pilot study
  • Musculoskeletal complaint
  • Economic evaluation
03

In context

Lead sponsor

Universidade Cidade de Sao Paulo is the lead sponsor of 42 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • pregnant women of usual risk in the 12th gestational week (gestational age determined by the date of the last menstruation or by the ultrasound examination)
  • with medical clearance to practice physical activity

Exclusion criteria

Exclusion Criteria:

  • practice of other physical activity during pregnancy
  • any medical , such as diabetes and hypertension
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
20 participants (estimated)

Study arms

  • No intervention
    Usual care

    Usual care group will perform the usual prenatal care indicated by the obstetrician and will receive an educational booklet.

  • Active comparator
    Pilates

    Pilates group will perform the usual prenatal care indicated by the obstetrician and will receive an educational booklet. Additionally, this group will receive an exercise program based on Pilates, twice a week, individually, throughout the gestational period.

    Other: Pilates exercises

Interventions

  • OtherPilates exercises

    Sessions will last 60 minutes: five minutes for warming up, 50 minutes for the practice of Pilates exercises, and five minutes for relaxing with the Swiss ball. The exercise protocol will be divided into three gestational phases, covering the entire gestational period, with different and specific objectives for each phase. In all phases, the exercises will be classified into three levels of difficulty: basic, intermediate, and advanced, according to the evolution of each pregnant woman throughout the practice of Pilates. Modifications will be allowed to facilitate or hinder the execution of the movement. The exercises will be performed in one or two sets of seven to 10 repetitions. The number of series, repetitions and exercises and interval time between them, as well as the level of difficulty of the exercises, will be gradually adjusted. The intensity of the exercises will vary between light and moderate and will be controlled by the Borg scale.

06

What researchers measure

Primary outcomes

  1. Acceptability measured using a 11-point numerical scale (0 = completely dissatisfied with the treatment results; 10 = completely satisfied with the treatment results)

    The participant's perception of the treatment result being satisfactory

    Time frame: 24th gestational week

  2. Acceptability measured using a 11-point numerical scale (0 = completely dissatisfied with the treatment results; 10 = completely satisfied with the treatment results)

    The participant's perception of the treatment result being satisfactory

    Time frame: 36th gestational week

  3. Acceptability measured using a 11-point numerical scale (0 = completely dissatisfied with the treatment results; 10 = completely satisfied with the treatment results)

    The participant's perception of the treatment result being satisfactory

    Time frame: From 7 to 15 days after delivery

  4. Suitability measured using 2 questions (one about the need of tailored exercises for the gestational needs and the other about the need of some adaptation during the execution of the exercises)

    Assesses whether the exercise program is suitable for the target audience or needs some adaptation

    Time frame: 24th gestational week

  5. Suitability measured using 2 questions (one about the need of tailored exercises for the gestational needs and the other about the need of some adaptation during the execution of the exercises)

    Assesses whether the exercise program is suitable for the target audience or needs some adaptation

    Time frame: 36th gestational week

  6. Suitability measured using 2 questions (one about the need of tailored exercises for the gestational needs and the other about the need of some adaptation during the execution of the exercises)

    Assesses whether the exercise program is suitable for the target audience or needs some adaptation

    Time frame: From 7 to 15 days after delivery

  7. Viability measured using a form developed for this study and filled by the physical therapist responsible for the treatment

    Assesses recruitment, retention, and participation rates, whether participants reached the end of the treatment program and, if not, why they dropped out

    Time frame: 24th gestational week

  8. Viability measured using a form developed for this study and filled by the physical therapist responsible for the treatment

    Assesses recruitment, retention, and participation rates, whether participants reached the end of the treatment program and, if not, why they dropped out

    Time frame: 36th gestational week

  9. Viability measured using a form developed for this study and filled by the physical therapist responsible for the treatment

    Assesses recruitment, retention, and participation rates, whether participants reached the end of the treatment program and, if not, why they dropped out

    Time frame: From 7 to 15 days after delivery

  10. Fidelity measured using an exercise checklist (list of all exercises that can be performed including the level of difficulty)

    Assesses the level of difficulty of the selected exercises

    Time frame: 24th gestational week

  11. Fidelity measured using an exercise checklist (list of all exercises that can be performed including the level of difficulty)

    Assesses the level of difficulty of the selected exercises

    Time frame: 36th gestational week

  12. Fidelity measured using an exercise checklist (list of all exercises that can be performed including the level of difficulty)

    Assesses the level of difficulty of the selected exercises

    Time frame: From 7 to 15 days after delivery

Secondary outcomes

  1. Occurrence of musculoskeletal complaint

    Time frame: 24th gestational week, 36th gestational week, and from seven to 15 days after delivery

  2. Number of days from randomization on which the musculoskeletal complaint occurred

    Time frame: 24th gestational week, 36th gestational week, and from seven to 15 days after delivery

  3. Delivery mode (normal or caesarean section)

    Time frame: From 7 to 15 days after delivery

  4. Apgar score (0 to 10)

    Reported at 1 minute and 5 minutes after birth, and at 5-minute intervals thereafter until 20 minutes for infants with a score less than 7

    Time frame: From 7 to 15 days after delivery

  5. Baby's birth weight

    Time frame: From 7 to 15 days after delivery

  6. Kinesiophobia measured using the Tampa Scale of Kinesiophobia in the occurrence of musculoskeletal complaint

    The total score ranges from 17 to 68 points, and the higher the score, the greater the degree of kinesiophobia.

    Time frame: 24th gestational week, 36th gestational week, and from 7 to 15 days after delivery

  7. Disability measured using the Patient Specific Functional Scale in the occurrence of musculoskeletal complaint

    11-point numerical scale (0 = unable to perform the activity; 10 = able to perform the activity at the same level as before the injury or problem)

    Time frame: 24th gestational week, 36th gestational week, and from 7 to 15 days after delivery

  8. Pain measured using the Pain Numerical Rating Scale in the occurrence of musculoskeletal complaint

    11-point numerical scale (0 = no pain; 10 = the worst possible pain)

    Time frame: 24th gestational week, 36th gestational week, and from 7 to 15 days after delivery

  9. Costs (healthcare costs, patient and family costs, and lost productivity costs) measured using a questionnaire specially developed for this study

    Time frame: Baseline, 24th gestational week, 36th gestational week, and from 7 to 15 days after delivery

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jul 2023; primary completion for Jun 2024, 11 months later.

How these figures are worked out, and which studies are left out of them.

Registered
May 18, 2023
First posted
Jun 15, 2023
StartEst.
Jul 1, 2023
Primary completionEst.
Jun 30, 2024
CompletionEst.
Dec 31, 2025
Last update
Jun 15, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 15, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05904925
Lead sponsor
Universidade Cidade de Sao Paulo
Responsible party
Cristina Maria Nunes Cabral (Professor, Universidade Cidade de Sao Paulo) — Principal investigator
First posted
Jun 15, 2023
Start date
Jul 1, 2023 (estimated)
Primary completion
Jun 30, 2024 (estimated)
Completion
Dec 31, 2025 (estimated)
Last update
Jun 15, 2023

Study contacts

Cristina MN Cabral, PhD
Contact
cristina.cabral@unicid.edu.br
55 11 21781214
Cristina MN Cabral, PhD
principal investigator · Universidade Cidade de São Paulo

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion